A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers by Tayob, Nabihah et al.
Biometrics 72, 1–?? DOI: 10.1111/j.1541-0420.2005.00454.x
December 2016
Web-based Supplementary Materials for A Bayesian Screening Approach for
Hepatocellular Carcinoma using Multiple Longitudinal Biomarkers
Nabihah Tayob1,∗, Francesco Stingo2, Kim-Anh Do1, Anna S. F. Lok3 and Ziding Feng1
1Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
2Department of Statistics, Computer Science, Applications “G. Parenti”, University of Florence, Florence, Italy
3Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, U.S.A.
*email: ntayob@mdanderson.org
This paper has been submitted for consideration for publication in Biometrics
Screening with Multiple Longitudinal Biomarkers 1
Web Appendix A. HALT-C Trial
Web Appendix A.1 Analysis data description
HCV cirrhosis patients are at high risk for HCC and are recommended to undergo regular
surveillance. Within the HALT-C Trial, 427 patients were diagnosed with cirrhosis at the
baseline biopsy. We excluded 18 patients not diagnosed with HCC but with less than 12
months of follow-up. Our analysis dataset consists of 361 control patients who were not
diagnosed with HCC during a median follow-up period of 78 months (range 15-109 months)
and 48 confirmed HCC cases. In Web Figure 1, we illustrate the subsets of patients in the
HALT-C Trial and the biomarkers measured during follow-up. We have local laboratory
tests for AFP at all the patient visits. DCP was measured at a central laboratory as part
of an ancillary study, which used stored samples collected during the first 42 months post-
randomization as per the trial protocol. We excluded biomarker data from visits that took
place during the last 12 months of follow-up in the controls to ensure that they did not have
HCC when biomarker data was collected.
[Web Figure 1 about here.]
In Web Figure 2 and 3 we plot the individual trajectories of AFP and DCP, respectively,
for all 48 HCC cases in the analysis cohort. In Web Figure 4 and 5 we plot the individual
trajectories of AFP and DCP, respectively, in 48 randomly selected patients that have at
least 12 months of follow-up and do not develop HCC during the study.
[Web Figure 2 about here.]
[Web Figure 3 about here.]
[Web Figure 4 about here.]
[Web Figure 5 about here.]
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Web Appendix A.2 Exploratory data analysis
The structure of our proposed model was based on initial exploratory data analysis of AFP
and DCP in cases and controls from the HALT-C Trial. In Web Figure 6, we plot the
histograms of the distribution of AFP and DCP before and after logarithmic transfromations
in control patients from the HALT-C Trial. In our model we assume that these transformed
markers have a normal distribution.
[Web Figure 6 about here.]
Next we evaluated whether the patient specific mean biomarker levels in the absence of
disease, θik, were correlated. For each control patient in the HALT-C Trial we calculated
their average log(AFP) and log(DCP+1) values. In Web Figure 7, we observe that there is
minimal correlation between the mean log(AFP) and log(DCP+1) levels in control patients.
Therefore we conclude that a simpler model that does not specify a joint prior for θik is
suitable for our analysis.
[Web Figure 7 about here.]
Next we considered the biomarker levels within two years of clinical diagnosis in HCC cases
in the HALT-C Trial. For each patient we fitted a simple linear model for both log(AFP)
and log(DCP+1) when patients had two or more observations within the two years prior to
clinical diagnosis. The subject specific slope is a rough estimate of γik for each biomarker.
In Web Figure 8, we observe that there is minimal correlation between the slopes log(AFP)
and log(DCP+1) levels in case patients with sufficient data. Therefore we conclude that a
simpler model that does not specify a joint prior for γik is suitable for our analysis.
[Web Figure 8 about here.]
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In the HALT-C analysis, we chose the values of the hyperparameters in the prior distribu-
tions for the biomarker specific parameters during exploratory analysis and they are listed
in Web Table 1.
The hyperparameters for µθ1 and µθ2 were chosen after fitting a linear mixed model for
AFP and DCP respectively in control patients from the HALT-C Trial. The hyperparameters
for µγ1 and µγ2 were chosen by examining the trajectories of AFP in HALT-C HCC cases
within two-years prior to clinical diagnosis (see Web Figure 8). The hyperparameters for
µτ1 and µτ2 were chosen to reflect prior knowledge that HCC is a fast growing cancer and
therefore on average we expect mean onset to be within 1 year prior to clinical diagnosis. For
στ1 and στ2, we set the hyperparameters to have the prior expected value of 0.75 such that all
the values in the support (2 years prior to clinical diagnosis) of the changepoint parameter
τ have non-negligible prior probability. For σθk and σγk (k = 1, 2), the hyperparameters
we have chosen encourage similar values for slope and intercepts across subjects (note that
these priors concentrate on very small values). We note that in Web Figure 18, the posterior
distribution for most of these parameters are not concentrated around values that have
high prior probability overall highlighting the weak influence of the hyperparameters on the
posterior inference.
[Web Table 1 about here.]
Web Appendix A.3 MCMC Convergence
[Web Figure 9 about here.]
[Web Figure 10 about here.]
Web Appendix A.4 Model assessment
[Web Figure 11 about here.]
[Web Figure 12 about here.]
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[Web Figure 13 about here.]
Web Appendix A.5 Prior sensitivity
The sensitivity of the results to the prior distributions was assessed by evaluating how the
mean posterior probability of an AFP and DCP changepoint varied in the 48 HCC cases
as the prior distributions for the parameters ηI , µI , µγ and µτ were changed. The posterior
probability of a changepoint is an important component of the model fit that affects the
performance of the screening algorithm. In Figures 3-6, we plot the posterior probability of
an AFP and DCP changepoint under three different prior distributions for each parameter.
For the MRF parameter ηI , our assumed prior is a Beta distribution with mean of 0.1.
In Web Figure 14, we consider Beta priors for ηI where the mean is 0.5 and 0.8 while
keeping the standard deviation similar to that of the assumed prior (SD=0.042). As we
increase the mean of the prior for ηI , there is little effect on the posterior probability of a
changepoint for those patients with a very low posterior probability of a changepoint to start
with. For those with a high posterior probability of a changepoint for one marker, increasing
parameter ηI increases the posterior probability of a changepoint for the other marker. This
is expected since we are increasing the strength of the connection between the markers. For
those with borderline values, a higher prior mean for ηI pulls both posterior probabilities of
a changepoints upwards.
For the other MRF parameter µI , we evaluated how the posterior probabilities of a
changepoint varied when the mean of the Beta prior of the logistic transformation of µI
was decreased to 0.4 or increased to 0.6, while keeping the standard deviation of the Beta
prior similar. In Web Figure 15 we see that for µI , there is more sensitivity in the posterior
probability of changepoints to the changes but the rankings of the patients are mostly
preserved. Spearman’s rank correlation was 0.994-0.997 for the posterior probability of an
AFP changepoint and 0.945-0.967 for the posterior probability of a DCP changepoint.
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In Web Figure 16 we observe that the posterior probability of changepoints are highly
sensitive to the prior of µγ. When we decreased the mean of the prior to 2 the posterior
probability of changepoints for AFP and DCP increased and conversely when we increased
the mean of the prior to 3.5 the posterior probability of changepoints for AFP and DCP
decreased. The inverse relationship is expected since a flatter slope would potentially apply
to more HCC cases. The choice of prior for the slope parameters in most studies of this
type is very important since it is rare to have sufficient data on cases to estimate these
well. The rankings of the patients for the posterior probability of an AFP changepoint are
preserved (Spearman’s rank correlation: 0.990-0.995) but that is not the case for the posterior
probability of an DCP changepoint (Spearman’s rank correlation: 0.618-0.845). Since we have
reduced follow-up for DCP, we expect that the prior selection is even more important for
this marker.
For µτ (Web Figure 17), we decreased the mean of the prior to 0.5 and increased it to 1.5.
In most patients we observed minimal sensitivity of the posterior probability of changepoints
to these changes.
[Web Figure 14 about here.]
[Web Figure 15 about here.]
[Web Figure 16 about here.]
[Web Figure 17 about here.]
[Web Figure 18 about here.]
Web Appendix A.6 Cross-validated analysis
[Web Figure 19 about here.]
For each method, we calculate the time of the first positive screen during the entire
screening period, within two years of clinical diagnosis and within one year of clinical
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diagnosis. In Web Table 2-4, the (i, j)th entry corresponds to the empirical mean percentage
of times the ith method has a positive screen first and the (j, i)th entry to the empirical mean
percentage of times the jth method has a positive screen first. The empirical mean percentage
of times where the ith and the jth methods have a positive screen at the same time is 100 -
(i, j)th entry - (j, i)th entry. For each comparison, we have highlighted (bold text) the higher
percentage.
[Web Table 2 about here.]
[Web Table 3 about here.]
[Web Table 4 about here.]
Web Appendix B. Methods
Web Appendix B.1 Markov Chain Monte Carlo Procedure: Computational Algorithm
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Step 1-S: Update parameters for s ∈ {1, . . . , S} and s∗ = 1 + 3(s− 1).
(1) Update µθk, k = 1, . . . , K: Sample µ
(s)
θk from N(µ0k∗ , σ
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(5) Update ηI :
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(a) Generate η∗I from its proposal distribution JηI (ηI |η
(s−1)
I ) = Beta(ã, b̃), where ã and
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(9) Update σ2τk, k = 1, . . . , K:
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Web Appendix B.2 Posterior risk calculations
For the (N + 1)th patient at screening time tij, the posterior risk of disease given their
screening history is:
P (DN+1 = 1|YN+1)
P (DN+1 = 0|YN+1)
=
P (YN+1|DN+1 = 1)
P (YN+1|DN+1 = 0)
× P (DN+1 = 1)
1− P (DN+1 = 1)
=
∏K
k=1 P (YN+1,k|DN+1 = 1)∏K
k=1 P (YN+1,k|DN+1 = 0)
× P (DN+1 = 1)
1− P (DN+1 = 1)
where YN+1,k = {Y(N+1)j′k, j′ = 1, . . . , j} and YN+1 = {YN+1,k, k = 1, . . . , K}. Each of the
components is calculated in the following algorithm:
Draw S samples from posterior distribution of the biomarker specific and Markov random






τk, for k = 1, . . . , K and µI and ηI . For each
patient i, at each time tij
• Calculate P{(Yi1k, . . . , Yijk)|Di = 0} for each k = 1, . . . , K.
– For each of the S posterior samples, draw θik from its predictive distribution N(µθk, σ
2
θk).









– Average the joint probabilities over the S samples to get an estimate of
P{(Yi1k, . . . , Yijk)|Di = 0}.
• For each of the S posterior samples, draw Ii from its predictive distribution MRF (µI , ηI).
• For each of the S posterior samples, draw an imputation of the unknown clinical diagnosis
time di from it’s empirical distribution in the study data.
• Calculate P{(Yi1k, . . . , Yijk)|Di = 1} for each k = 1, . . . , K.
– For each of the S posterior samples, draw θik from its predictive distribution N(µθk, σ
2
θk).
– Extract the S posterior samples of Iik.
– For each of the S samples, if Iik = 0
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– Or if Iik = 1
· Draw log(γik) from its predictive distribution N(µγk, σ2γk).
· Draw τik from its predictive distribution TN[di−τ∗k ,di](di − µτk, σ
2
τk).







– Average the joint probabilities over the S samples to get an estimate of
P{(Yi1k, . . . , Yijk)|Di = 1}.
Web Appendix C. Simulations
[Web Table 5 about here.]
[Web Table 6 about here.]
Web Appendix C.1 Alternative methods under consideration
Univariate fully Bayesian screening algorithm
The univariate fully Bayesian (uFB) screening algorithm proposed by Skates et al. (2001)
assumes that a single biomarker levels vary randomly around a constant mean in the absence
of disease and after disease onset, the biomarker may or may not change over time. Our
proposed methodology reduces to that of Skates et al. (2001) when there is only a single
marker (i.e. K=1). For completeness we include the uFB model here.
For control patients, with Di = 0, the biomarker level is assumed to randomly fluctuate
around a constant mean θi1 and follows the model
Yij1 = θi1 + εij1,
where εij1 ∼ N(0, σ21). For cases, with Di = 1, we define an unobserved indicator Ii1 to
distinguish between the two possible models for the marker. If Ii1 = 0, then we assume
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that the marker level does not increase after disease onset and follows the same model as
control patients, i.e Yij1 = θi1 + εij1. If Ii1 = 1, then we assume the marker level randomly
fluctuates around a constant mean θi1 until an unobserved change-point time τi1, after which
the biomarker level increases linearly at a rate of γi1 with model
Yij1 = θi1 + γi1(tij − τi1)+ + εij1,
where (.)+ indicates the positive part of the expression.
We assume the uninformative Jeffreys’ prior, 1/σ21, for the variability of the biomarker. The
constant mean biomarker level θi1 is assumed to be normally distributed with mean µθ1 and
variance σ2θ1. The case-specific random effect for the rate γi1 is assumed to be log-normally
distributed, i.e. log(γi1) ∼ N(µγ1, σ2γ1). The change-point time τi1 is assumed to occur within
τ ∗1 years prior to diagnosis di. The parameter τ
∗
1 is fixed and reflects the known preclinical
behavior of the disease. In the case of HCC, which is a fast growing cancer, τ ∗1 is set to be
2 years and the onset of HCC is assumed to be at most 2 years prior to clinical diagnosis
of HCC. Therefore the change-point time τi1 is assumed to follow a truncated normal (TN)
distribution with lower bound di− τ ∗1 , upper bound di, mean di−µτ1 and variance σ2τ1. Ii1 is
assumed to follow a Bernoulli distribution with parameter π1. Note that the Markov Random
Field prior that we use in the proposed joint model reduces to a Bernoulli distribution with
parameter π1 = exp(µI)/{1 + exp(µI)} when K = 1.
Univariate parametric empirical Bayes screening algorithm
The univariate parametric empirical Bayes (uEB) screening algorithm proposed by McIntosh
and Urban (2003) defines a patient and screen specific threshold that incorporates both the
prior screening history of the patient and a model for the biomarker behavior in control
patients. In control patients, with Di = 0, the biomarker level is assumed to randomly
fluctuate around a constant mean θi1 and follows a hierarchical distribution:
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Yij1|θi1 ∼ N(θi1, σ21)
θi1 ∼ N(µθ1, σ2θ1)
I.e. given the patient-specific mean θi1, the transformed biomarker levels Yij1 are independent
and identically distributed with mean θi1 and variance σ
2
1 and θi1 itself is normally distributed
with mean µθ1 and variance σ
2
θ1. The within-subject variance σ
2
1 and between-subject variance
σ2θ1 are key measures that effect the performance of the PEB algorithm. Yij can be centered





Zij|µi ∼ N(µi, 1−B1)







Note that a simple calculation verifies that the marginal distribution of Zij is the standard
normal distribution.
The standard threshold (ST) approach ignores prior screening history of the patient and
instead uses the same threshold for all patients. One possible approach for determining this
threshold is to use the above model, which describes the transformed biomarker distribution
in the control population, to specify a threshold that controls the population-wide false
positive rate (FPR). Since Zij is assumed to follow a standard normal distribution, then
Pr(Zij > z1−f0) = f0 where z1−f0 is the 100(1 − f0) percentile of the standard normal
distribution. Therefore, using the standard threshold screening rule, patient i has a positive
screen at the jth screening visit if Zij > z1−f0 .
If the patient’s mean biomarker level (µi) were known, we could define an individually
tailored screening rule that still ensures the population-wide FPR is not more than f0 since
given µi, (Zij − µi)/
√
1−B1 follows a standard normal distribution. Therefore Pr{(Zij −
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µi)/
√
1−B1 > z1−f0 |µi} = f0 and patient i has a positive screen at the jth screening visit if
Zij > µi + z1−f0
√
1−B1.
However µi is not known, so instead we use the parametric empirical Bayes (PEB) estimate
of this parameter. This estimate, denoted by µ̂ij, is a weighted average of the population
mean (which is 0 in this case) and the sample average of the patients screening history. The
PEB screening rule then indicates a positive screen for patient i at the jth screening visit if
Zij > µ̂ij + z1−f0
√
1−B1Bj, (1)
where µ̂ij = 0 ∗ (1−Bj) + Z̄ij ∗Bj, Z̄ij = 1j−1
∑j−1




To implement the PEB screening algorithm, we require estimates for the parameters µθ1,
σ21 and σ
2
θ1. These can be obtained by fitting a linear mixed model with a random intercept
in the control patients from the training data. We then apply the PEB screening rule to all
the screenings conducted in the validation data.
Independent multivariate fully Bayesian screening algorithm
The independent multivariate fully Bayesian (mFB-I) screening algorithm incorporates all
K biomarkers into the model but assumes the markers are independent (i.e. there is no MRF
prior to connect the biomarkers). Instead the priors for each indicator Iik are assumed to
be independent Bernoulli distributions with parameter πk, for k = 1, . . . , K. The rest of the
model remains the same (see Section 3 of the main manuscript).
Web Appendix C.2 Additional Simulation Results
[Web Table 7 about here.]
[Web Table 8 about here.]
[Web Table 9 about here.]
The patient-level sensitivity is defined to be the percentage of detectable cases with a
positive screen after disease onset (italicized diagonal of Web Table 10 contains the empirical
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mean ROC(0.1) based on this definition of sensitivity). For each method, we calculate the
time of the first positive screen after disease onset. In Web Table 10, the (i, j)th entry
corresponds to the empirical mean percentage of times the ith method has a positive screen
first and the (j, i)th entry to the empirical mean percentage of times the jth method has
a positive screen first among the detectable cases. The empirical mean percentage of times
where the ith and the jth methods have a positive screen at the same time is 100 - (i, j)th entry
- (j, i)th entry. For each comparison, we have highlighted (bold text) the higher percentage.
[Web Table 10 about here.]
In our model, we assume that the variance of each biomarker (σ2k, k = 1, .., K) is constant
and not subject to change. We evaluated the impact of this assumption in a series of simu-
lation studies where we generated data that included increasing variability in the biomarker
after the changepoint in HCC cases but left our model (as described in Section 3) unchanged.
The simulation study adapted Scenario A to generate the data and assumed that in controls
and HCC cases with no changepoint, σ2k, k = 1, .., K is constant. In HCC cases with a
changepoint, we assumed the standard deviation of each marker increases linearly with rate
δk, k = 1, .., K. The results for Scenario A (δk = 0, k = 1, .., 3), Scenario E (δk = 0.1,
k = 1, .., 3), Scenario F (δk = 0.1, k = 1, .., 3), and Scenario G (δk = 0.1, k = 1, .., 3) are
presented in Table 11. The increasing variability has minimal impact on the performance of
the joint multivariate fully Bayesian screening approach which assumes constant variance.
Therefore while it may be important to consider a model that allows for a corresponding
changepoint in the variance of the biomarker in other scenarios, it is beyond the scope of our
current project and simulation studies show that our results are robust to our assumption
in biomarker trajectories that mimic those observed in the HALT-C Trial.
[Web Table 11 about here.]
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Web Figure 1. Standards for Reporting of Diagnostic accuracy (STARD) flow diagram
and follow-up schedule in the HALT-C Trial. In our analysis dataset (highlighted in red), we
have 361 patients with no HCC and 48 confirmed HCC datasets.
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Web Figure 2. AFP trajectories for all 48 HCC cases in our analysis cohort.
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Web Figure 3. DCP trajectories for all 48 HCC cases in our analysis cohort.
22 Biometrics, December 2016











−8 −6 −4 −2
Subject 49 Subject 50
−8 −6 −4 −2
Subject 51 Subject 52
−8 −6 −4 −2
Subject 53 Subject 54
−8 −6 −4 −2
Subject 55










Subject 63 Subject 64 Subject 65 Subject 66 Subject 67 Subject 68 Subject 69










Subject 77 Subject 78 Subject 79 Subject 80 Subject 81 Subject 82 Subject 83











−8 −6 −4 −2
Subject 92 Subject 93
−8 −6 −4 −2
Subject 94 Subject 95
−8 −6 −4 −2
Subject 96
Web Figure 4. AFP trajectories for 48 randomly selected patients with no HCC from our
analysis cohort.
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Web Figure 5. DCP trajectories for 48 randomly selected patients with no HCC from
our analysis cohort.



































































Web Figure 6. Distribution of AFP and DCP before and after logarithmic transforma-
tions in control patients from the HALT-C Trial.
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Web Figure 7. Examining correlation between average log(AFP) and log(DCP+1) values
in controls from the HALT-C Trial.
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Web Figure 8. Examining correlation between log(AFP) trajectory and log(DCP+1)
trajectory within two years of clinical diagnosis of HCC in cases from the HALT-C Trial.
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2, µI , ηI) for chain
1 (red) and chain 2 (blue) from the HALT-C Trial.
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for chain 1 (red) and chain 2 (blue) from the HALT-C Trial.
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Web Figure 11. Model goodness of fit for AFP and DCP slopes in controls from the
HALT-C Trial
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Web Figure 12. Model goodness of fit for AFP and DCP trajectories in four HCC cases
from the HALT-C Trial.
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Web Figure 13. Examining the residuals (εijk) for AFP and DCP in HCC cases (left
column) and controls (right column) from the HALT-C Trial. There is no evidence of a time
trend in the residuals.
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Web Figure 14. Sensitivity Analysis: ηI . The posterior probabilities for each HCC case
are connected with gray line.
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Web Figure 15. Sensitivity Analysis: µI . The posterior probabilities for each HCC case
are connected with gray line.
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Web Figure 16. Sensitivity Analysis: µγ. The posterior probabilities for each HCC case
are connected with gray line.
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Web Figure 17. Sensitivity Analysis: µτ . The posterior probabilities for each HCC case
are connected with gray line.











































































































































































































Web Figure 18. Posterior distribution for each parameter in the model. The prior
distributions are overlayed (solid line).
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Web Figure 19. Cross-valiated ROC curve for mFB-J: joint multivariate fully bayesian
(solid black line), mFB-I: independent multivariate fully bayesian (grey line), uFB: univariate
fully bayesian (solid red line for AFP and solid blue line for DCP) and uEB: parametric
empirical bayes (dashed red line for AFP and dashed blue line for DCP).
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AFP (k=1) DCP (k=2) AFP (k=1) DCP (k=2)
µθk N(2, 0.1) N(3, 0.1) σ
2
θk IG(2, 0.05) IG(2, 0.05)
[1.380, 2.620] [2.380, 3.620] [0.009, 0.206] [0.009, 0.206]
µγk N(log(16), 0.05) N(log(16), 0.05) σ
2
γk IG(4, 0.1) IG(4, 0.1)
[2.332, 3.208] [2.332, 3.208] [0.011, 0.092] [0.011, 0.092]
µτk N(1, 0.1) N(1, 0.1) σ
2
τk IG(10, 6.19) IG(10, 6.19)
[0.380, 1.620] [0.380, 1.620] [0.362, 1.291] [0.362, 1.291]
Web Table 1
Prior distributions of AFP and DCP specific parameters in the joint model. The 2.5th and 97.5th percentiles for
each distribution is given below in brackets.
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mFB-J mFB-I uFB AFP uFB DCP uEB AFP uEB DCP
mFB-J · 25.00 33.00 52.00 29.00 68.00
mFB-I 24.50 · 35.50 49.00 23.50 59.00
uFB AFP 20.00 31.00 · 48.00 24.00 62.00
uFB DCP 36.50 29.00 41.50 · 45.50 44.50
uEB AFP 26.50 29.00 28.50 48.00 · 60.00
uEB DCP 19.00 19.00 29.50 16.50 27.50 ·
Web Table 2
Percentage of times each method has a positive screen first in the HALT-C Trial. The (i, j)th entry corresponds to
the cross-validated percentage of times the ith method has a positive screen first. mFB-J: joint multivariate fully
Bayesian, mFB-I: independent multivariate fully Bayesian, uFB: univariate fully Bayesian and uEB: parametric
empirical Bayes
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mFB-J mFB-I uFB AFP uFB DCP uEB AFP uEB DCP
mFB-J · 4.50 16.50 46.30 4.50 40.74
mFB-I 6.00 · 16.50 45.37 6.50 39.81
uFB AFP 8.00 10.50 · 47.22 8.00 41.67
uFB DCP 12.04 9.26 25.00 · 8.33 2.78
uEB AFP 29.00 29.50 33.00 52.78 · 47.22
uEB DCP 34.26 31.48 36.11 37.96 25.00 ·
Web Table 3
Percentage of times each method has a positive screen first within 2-years of clinical diagnosis in the HALT-C Trial.
The (i, j)th entry corresponds to the cross-validated percentage of times the ith method has a positive screen first.
mFB-J: joint multivariate fully Bayesian, mFB-I: independent multivariate fully Bayesian, uFB: univariate fully
Bayesian and uEB: parametric empirical Bayes
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mFB-J mFB-I uFB AFP uFB DCP uEB AFP uEB DCP
mFB-J · 4.50 10.50 50.93 12.50 44.44
mFB-I 4.00 · 10.50 42.59 12.50 36.11
uFB AFP 6.00 6.50 · 47.22 10.00 43.52
uFB DCP 13.89 10.19 23.15 · 16.67 0.00
uEB AFP 18.50 21.00 20.50 55.56 · 39.81
uEB DCP 29.63 25.93 29.63 34.26 25.93 ·
Web Table 4
Percentage of times each method has a positive screen first within 1-years of clinical diagnosis in the HALT-C Trial.
The (i, j)th entry corresponds to the cross-validated percentage of times the ith method has a positive screen first.
mFB-J: joint multivariate fully Bayesian, mFB-I: independent multivariate fully Bayesian, uFB: univariate fully
Bayesian and uEB: parametric empirical Bayes
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Parameter Scenario A Scenario B Scenario C
σ21 0.23 0.23 0.23
µθ1 2.43 2.43 2.43
σ2θ1 0.79 0.79 0.79
µγ1 1.87 0.87 1.87
σ2γ1 1.61 0.3 0.3
µτ1 1.05 1.05 1.05
σ2τ1 0.82 0.82 0.82
σ22 1.35 1.35 1.35
µθ2 3.10 3.10 3.10
σ2θ2 0.80 0.80 0.80
µγ2 1.92 0.92 0.92
σ2γ2 0.05 0.05 0.05
µτ2 0.56 0.56 0.56
σ2τ2 0.58 0.58 0.58
σ23 0.80 0.80 0.80
µθ3 2.75 2.75 2.75
σ2θ3 0.79 0.79 0.79
µγ3 1.00 0.65 0.65
σ2γ3 0.20 0.10 0.10
µτ3 0.75 0.75 0.75
σ2τ3 0.70 0.70 0.70
µI 0.15 0.15 0.15
ηI 0.1 0.1 0.1
Web Table 5
Fixed parameter values used in simulation study to generate data.
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Marker (1) (k=1) Marker (2) (k=2) Marker (3) (k=3)
µθk N(2, 0.1) N(3, 0.1) N(2, 0.1)
σ2θk IG(2, 0.05) IG(2, 0.05) IG(2, 0.05)
µγk N(log(16), 0.05) N(log(16), 0.05) N(log(16), 0.05)
σ2γk IG(4, 0.1) IG(4, 0.1) IG(4, 0.1)
µτk N(1, 0.1) N(1, 0.1) N(1, 0.1)




ηI ∼ Beta(5, 45)
Web Table 6
Prior distributions for the joint model parameters that were used in all scenarios of the simulations.
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Scenario D
Biomarker mFB-J mFB-I uFB uEB ST
(1)
78.38 (0.46) 78.77 (0.42)
63.43 (0.49) 62.90 (0.50) 49.33 (0.52)
(2) 60.18 (0.54) 59.48 (0.54) 53.07 (0.53)
(3) 54.79 (0.54) 54.79 (0.52) 44.34 (0.53)
Web Table 7
Summary of simulation results in 200 studies: empirical mean ROC(0.1) (empirical standard error of the mean).
mFB-J: joint multivariate fully Bayesian, mFB-I: independent multivariate fully Bayesian, uFB: univariate fully
Bayesian, uEB: parametric empirical Bayes and ST: single threshold
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Scenario A
Biomarker mFB-J mFB-I uFB uEB ST
(1)
81.75 (0.41) 81.67 (0.41)
67.75 (0.49) 66.61 (0.50) 51.28 (0.56)
(2) 64.20 (0.56) 63.03 (0.51) 55.48 (0.52)
(3) 58.58 (0.52) 58.41 (0.49) 46.88 (0.50)
Scenario B
Biomarker mFB-J mFB-I uFB uEB ST
(1)
72.21 (0.46) 71.75 (0.47)
63.97 (0.48) 64.18 (0.47) 45.01 (0.53)
(2) 54.52 (0.54) 54.56 (0.55) 44.81 (0.49)
(3) 55.83 (0.54) 54.82 (0.52) 41.97 (0.55)
Scenario C
Biomarker mFB-J mFB-I uFB uEB ST
(1)
77.96 (0.43) 77.63 (0.42)
70.91 (0.47) 69.35 (0.47) 55.91 (0.49)
(2) 54.55 (0.51) 55.08 (0.55) 45.20 (0.51)
(3) 56.18 (0.54) 54.71 (0.46) 42.22 (0.50)
Scenario D
Biomarker mFB-J mFB-I uFB uEB ST
(1)
78.62 (0.44) 78.82 (0.42)
63.67 (0.48) 62.99 (0.50) 49.36 (0.52)
(2) 60.26 (0.52) 59.39 (0.52) 52.92 (0.51)
(3) 54.77 (0.53) 54.67 (0.51) 44.28 (0.51)
Web Table 8
Summary of simulation results in 200 studies: empirical mean sensitivity corresponding to threshold established in
training data (empirical standard error of the mean). mFB-J: joint multivariate fully Bayesian, mFB-I: independent
multivariate fully Bayesian, uFB: univariate fully Bayesian, uEB: parametric empirical Bayes and ST: single
threshold.
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Scenario A
Biomarker mFB-J mFB-I uFB uEB ST
(1)
87.40 (0.08) 87.48 (0.08)
88.46 (0.07) 88.36 (0.07) 88.55 (0.13)
(2) 88.71 (0.07) 88.65 (0.07) 88.64 (0.10)
(3) 89.13 (0.07) 89.03 (0.07) 89.04 (0.10)
Scenario B
Biomarker mFB-J mFB-I uFB uEB ST
(1)
88.32 (0.08) 88.36 (0.07)
88.69 (0.08) 88.61 (0.07) 88.91 (0.13)
(2) 89.47 (0.07) 89.31 (0.07) 89.30 (0.10)
(3) 89.36 (0.07) 89.34 (0.07) 89.25 (0.11)
Scenario C
Biomarker mFB-J mFB-I uFB uEB ST
(1)
87.78 (0.08) 87.81 (0.08)
88.30 (0.07) 88.16 (0.07) 88.21 (0.13)
(2) 89.49 (0.07) 89.24 (0.07) 89.30 (0.09)
(3) 89.41 (0.07) 89.36 (0.07) 89.30 (0.10)
Scenario D
Biomarker mFB-J mFB-I uFB uEB ST
(1)
87.46 (0.08) 87.36 (0.08)
88.40 (0.07) 88.32 (0.08) 88.43 (0.13)
(2) 88.86 (0.07) 88.74 (0.07) 88.74 (0.10)
(3) 89.19 (0.07) 89.06 (0.07) 89.07 (0.11)
Web Table 9
Summary of simulation results in 200 studies: empirical mean specificity corresponding to threshold established in
training data (empirical standard error of the mean). mFB-J: joint multivariate fully Bayesian, mFB-I: independent
multivariate fully Bayesian, uFB: univariate fully Bayesian, uEB: parametric empirical Bayes and ST: single
threshold.
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mFB-J mFB-I uFB (1) uFB (2) uFB (3) uEB (1) uEB (2) uEB (3)
mFB-J 77.49 2.30 31.32 41.17 48.32 29.85 40.04 47.00
mFB-I 2.24 77.48 31.06 41.15 48.05 29.89 40.08 46.89
uFB (1) 5.82 5.38 53.15 35.46 37.96 5.37 34.66 37.80
uFB (2) 6.87 6.77 26.17 46.98 32.04 25.42 4.79 31.07
uFB (3) 6.72 6.56 21.43 24.40 39.87 20.78 24.06 5.28
uEB (1) 13.75 13.86 15.14 40.98 43.57 59.19 38.69 41.52
uEB (2) 13.77 13.71 31.18 14.72 38.22 28.84 53.78 35.54
uEB (3) 13.37 13.38 27.18 30.50 16.00 24.81 28.14 47.20
Web Table 10
Percentage of times each method has a positive screen first after disease onset in Scenario A of the simulation study.
The (i, j)th entry corresponds to the empirical mean percentage of times the ith method has a positive screen first.
The (i, i)th corresponds to the empirical mean ROC(0.1) of the ith method after disease onset. mFB-J: joint
multivariate fully Bayesian, mFB-I: independent multivariate fully Bayesian, uFB: univariate fully Bayesian and
uEB: parametric empirical Bayes.
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